Analysis Tools
immune system
|
• ex vivo activated CD4 and CD8 T cells exhibit increased chemotaxis to S1P protein in contrast to wild-type controls which lose migratory response to S1P
|
|
• CD4 splenic T cells exhibit a 60-70% decrease in homing to lymph nodes, Peyers patches, and spleen, but not to thymus, lungs, kidneys, liver or brain
|
|
• 10-34% decrease in proliferative response from stimulated T cells using TCR-specific mAbs or mixed splenic mononuclear leukocytes from BALB/c mice
|
|
• adoptive transfer of activated CD4 and CD8 splenic T cells to wild-type recipients results in 2.2 fold increase of activated T cells in blood and a 1.4 fold increase in spleen
• no shift in CD4:CD8 T cell ratio is observed
|
|
• increased number of CD3 T cells in blood, but not in lymph nodes or spleen as compared to controls
• CD3 T cells represent 40% of total blood leukocytes as compared to 25% in wild-type
|
|
• adoptive transfer of activated CD4 and CD8 splenic T cells to wild-type recipients results in a 1.5 fold decrease in lymph nodes
• no shift in CD4:CD8 T cell ratio is observed
|
|
• reduced delayed type hypersensitivity response following either DNFB-induced ear response or NP OSu-induced footpad response as compared to wild-type
• T cells from cervical lymph nodes of DNFB-challenged mice express CD69, a marker of early lymphocyte activation
|
|
• following TNP-KLH immunization, IgG2b antibody levels increase 5 fold as compared to a 30 fold increase in wild-type
• following TNP-KLH immunization, IgE antibody levels are increased at 14 and 21 days as compared to wild-type
|
|
• increased levels of plasma IgE as compared to wild-type
• following TNP-KLH immunization, IgE antibody levels are increased at 14 and 21 days as compared to wild-type
|
hematopoietic system
|
• ex vivo activated CD4 and CD8 T cells exhibit increased chemotaxis to S1P protein in contrast to wild-type controls which lose migratory response to S1P
|
|
• CD4 splenic T cells exhibit a 60-70% decrease in homing to lymph nodes, Peyers patches, and spleen, but not to thymus, lungs, kidneys, liver or brain
|
|
• 10-34% decrease in proliferative response from stimulated T cells using TCR-specific mAbs or mixed splenic mononuclear leukocytes from BALB/c mice
|
|
• adoptive transfer of activated CD4 and CD8 splenic T cells to wild-type recipients results in 2.2 fold increase of activated T cells in blood and a 1.4 fold increase in spleen
• no shift in CD4:CD8 T cell ratio is observed
|
|
• increased number of CD3 T cells in blood, but not in lymph nodes or spleen as compared to controls
• CD3 T cells represent 40% of total blood leukocytes as compared to 25% in wild-type
|
|
• adoptive transfer of activated CD4 and CD8 splenic T cells to wild-type recipients results in a 1.5 fold decrease in lymph nodes
• no shift in CD4:CD8 T cell ratio is observed
|
|
• increased levels of plasma IgE as compared to wild-type
• following TNP-KLH immunization, IgE antibody levels are increased at 14 and 21 days as compared to wild-type
|
cellular
|
• ex vivo activated CD4 and CD8 T cells exhibit increased chemotaxis to S1P protein in contrast to wild-type controls which lose migratory response to S1P
|
|
• CD4 splenic T cells exhibit a 60-70% decrease in homing to lymph nodes, Peyers patches, and spleen, but not to thymus, lungs, kidneys, liver or brain
|
|
• 10-34% decrease in proliferative response from stimulated T cells using TCR-specific mAbs or mixed splenic mononuclear leukocytes from BALB/c mice
|
